1. Home
  2. ATYR vs TRVG Comparison

ATYR vs TRVG Comparison

Compare ATYR & TRVG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATYR
  • TRVG
  • Stock Information
  • Founded
  • ATYR 2005
  • TRVG 2005
  • Country
  • ATYR United States
  • TRVG Germany
  • Employees
  • ATYR N/A
  • TRVG N/A
  • Industry
  • ATYR Biotechnology: Biological Products (No Diagnostic Substances)
  • TRVG EDP Services
  • Sector
  • ATYR Health Care
  • TRVG Technology
  • Exchange
  • ATYR Nasdaq
  • TRVG Nasdaq
  • Market Cap
  • ATYR 327.0M
  • TRVG 306.5M
  • IPO Year
  • ATYR 2015
  • TRVG N/A
  • Fundamental
  • Price
  • ATYR $3.50
  • TRVG $5.19
  • Analyst Decision
  • ATYR Strong Buy
  • TRVG Hold
  • Analyst Count
  • ATYR 6
  • TRVG 5
  • Target Price
  • ATYR $18.60
  • TRVG $2.94
  • AVG Volume (30 Days)
  • ATYR 1.7M
  • TRVG 123.8K
  • Earning Date
  • ATYR 03-13-2025
  • TRVG 04-29-2025
  • Dividend Yield
  • ATYR N/A
  • TRVG N/A
  • EPS Growth
  • ATYR N/A
  • TRVG N/A
  • EPS
  • ATYR N/A
  • TRVG N/A
  • Revenue
  • ATYR $235,000.00
  • TRVG $477,118,749.00
  • Revenue This Year
  • ATYR $1,387.23
  • TRVG $9.85
  • Revenue Next Year
  • ATYR $873.22
  • TRVG $6.77
  • P/E Ratio
  • ATYR N/A
  • TRVG N/A
  • Revenue Growth
  • ATYR N/A
  • TRVG N/A
  • 52 Week Low
  • ATYR $1.42
  • TRVG $1.60
  • 52 Week High
  • ATYR $4.66
  • TRVG $5.45
  • Technical
  • Relative Strength Index (RSI)
  • ATYR 49.19
  • TRVG 69.30
  • Support Level
  • ATYR $3.63
  • TRVG $3.90
  • Resistance Level
  • ATYR $3.94
  • TRVG $5.45
  • Average True Range (ATR)
  • ATYR 0.33
  • TRVG 0.36
  • MACD
  • ATYR 0.01
  • TRVG 0.09
  • Stochastic Oscillator
  • ATYR 50.53
  • TRVG 85.56

About ATYR aTyr Pharma Inc. Common Stock

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

About TRVG trivago N.V.

trivago NV is a hotel search company focused on reshaping the way travelers search for and compare hotels while enabling hotel advertisers to grow their businesses by providing access to a broad audience of travelers through the company's websites and apps. The platform allows travelers to make informed decisions by personalizing their hotel search and providing access to a deep supply of hotel information and prices. The company operates in three operating segments namely the Americas, Developed Europe, and the Rest of the World. It derives a majority of revenue from the Developed Europe segment. The Developed Europe segment is comprised of Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, Malta, the Netherlands, Norway, Portugal, Spain, Sweden, and others.

Share on Social Networks: